Saratov JOURNAL of Medical and Scientific Research

Magnetic resonance imaging in the diagnosis of bladder cancer (review)

Year: 2019, volume 15 Issue: №3 Pages: 662-666
Heading: Urology Article type: Review
Authors: Bobylev D.A., Chekhonatskaya M.L., Rossolovsky A.N., Ponukalin A.N., Kryuchkov I.A., Kondratieva O.A., Zakharova N.B., Abramova A.P., Popkov V.M.
Organization: Saratov State Medical University

The current review represents possibilities of magnetic-resonance imaging in bladder cancer diagnostics. The most important indicator that determines the bladder cancer prognosis and surgical treatment tactics is the muscle wall invasion. Dynamic-contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging can determine the depth of invasion, although although both are susceptible to over-staging. Magnetic resonance imaging and computed tomography have approximately the same accuracy in determining perivesical invasion as well as in relation to metastatic lymph nodes less than 8 mm in diameter. A promising new technique is the ultra-small paramagnetic iron oxide particles-enhanced magnetic resonance imaging.

1 Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2 Kaprin AD, Apolihin Ol, Sivkov AV, et al. Analysis of uronephrological morbidity and mortality in the Russian Federation for period 2002-2014 according to the statistics. Experimental and clinical urology 2016; (3): 4-13.
3 Karyakin OB, Ivanov SA, Kaprin AD. Bladder cancer: what's new in 2017-2018. Oncourology 2018; 14 (4): 110-7.
4 Matveev ВР Clinical Oncourology. Moscow, 2011; 934 p.
5 Safiullin KN. Treatment of non-muscular-invasive bladder cancer: DSc abstract. Obninsk, 2012; 48 p.
6 Chisov VI, Alekseev BYa, Rusakov IG. Oncourology: national guidelines. Moscow: GEOTAR-Media, 2012; 688 p.
7 Mikich DH. Organ-preserving treatment for invasive bladder cancer. Oncourology 2005; 2: 27-32.
8 Kogan Ml. Bladder cancer (classic and innovations). Moscow: Medforum, 2017; 262 p.
9 MacVicar AD. Bladder cancer staging. BJU Int 2000; 86(Suppl 1): 111-22.
10 Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long- term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75.
11 Dutta SC, Smith JA Jr, Shappell SB, et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001; 166: 490-3.
12 Ficarra V, Dalpiaz O, Alrabi N, et al. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 2005; 95: 786-90.
13 Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007; 51: 137-49.
14 Svatek RS, Shariat SF, Novara G, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 2011; 107: 898-904.
15 Zhang J, Gerst S, Lefkowitz RA, et al. Imaging of bladder cancer. Radiol Clin North Am 2007; 45: 183-205.
16 Wong You Cheong JJ, Woodward PJ, et al. From the Archives of the AFIP: neoplasms of the urinary bladder: radiologic-pathologic correlation. Radiographics 2006; 26: 553-80.
17 Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-25.
18 Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007; 188: 1622-35.
19 Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007; 25: 4104-9.
20 Popkov VM, Chekhonatskaya ML, Zuev VV. Magnetic resonance diffusion-weighted imaging in the diagnosis of bladder cancer. Medical Bulletin of Bashkortostan 2015; 10 (3): 188-9.
21 Kobayashi S, Кода F, Yoshida S, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. Eur Radiol 2011; 21: 2178-86.
22 Cowan NC, Crew JP. Imaging bladder cancer. Curr Opin Urol 2010; 20: 409-13.
23 Kim B, Semelka RC, Ascher SM, et al. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 1994; 193:239-45.
24 Totaro A, Pinto F, Brescia A, et al. Imaging in bladder cancer: present role and future perspectives. Urol Int 2010; 85: 373-80.
25 TekesA, Kamel I, Imam K, et al. MR imaging features of transitional cell carcinoma of the urinary bladder. AJR Am J Roentgenol 2003; 180: 771-7.
26 Tekes A, Kamel I, Imam K, et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR Am J Roentgenol 2005; 184: 121-7.
27 Barentsz JO, Jager GJ, van Vierzen PB, et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. Radiology 1996; 201: 185-93.
28 Hayashi N, Tochigi H, Shiraishi T, et al. A new staging criterion for bladder carcinoma using gadolinium- enhanced magnetic resonance imaging with an endorectal surface coil: a comparison with ultrasonography. BJU Int 2000; 85: 32-6.
29 Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: diffusion-weighted MR imaging — accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009; 251: 112-21.
30 El-Assmy A, Abou-EI-Ghar ME, Mosbah A, et al. Bladder tumour staging: comparison of diffusion-and T2- weighted MR imaging. Eur Radiol 2009; 19: 1575-81.
31 Canter D, Long C, Kutikov A, et al. Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int 2011; 107: 58-62.
32 Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-66.
33 Kim JK, Park SY, Ahn HJ, et al. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology 2004; 231: 725-31.
34 Barentsz JO, Engelbrecht MR, Witjes JA, et al. MR imaging of the male pelvis. Eur Radiol 1999; 9: 1722-36.
35 Deserno WM, Harisinghani MG, Taupitz M, et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004; 233: 449-56.
36 SaokarA, Islam T, Jantsch M, et al. Detection of lymph nodes in pelvic malignancies with Computed Tomography and Magnetic Resonance Imaging. Clin Imaging 2010; 34: 361-6.
37 Jensen TK, Holt P, Gerke O, et al. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucosepositronemissiontomography /computed axial tomography and magnetic resonance imaging: correlation with histopathology. Scand J Urol Nephrol 2011; 45: 122-8.
38 Papalia R, Simone G, Grasso R, et al. Diffusion-weighted magnetic resonance imaging in patients selected for radical cystectomy: detection rate of pelvic lymph node metastases. BJU Int 2012; 109: 1031-6.
39 Bellin MF, Roy О Magnetic resonance lymphography Curr Opin Urol 2007; 17: 65-9.
40 Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009; 55:761-9.
41 Dobson MJ, Carrington BM, Collins CD, et al. The assessment of irradiated bladder carcinoma using dynamic contrast-enhanced MR imaging. Clin Radiol 2001; 56: 94-8.
42 Schrier BP, Peters M, Barentsz JO, et al. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol 2006; 49: 698-703.
43 Yoshida S, Кода F, Kawakami S, et al. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology 2010; 75: 387-91.

2019_03_662-666.pdf313.28 KB

No votes yet